Integrating PD-L1-targeted radioligand with protein degradation for precision tumor theranostics
Journal of Controlled Release · 2026
DOI: 10.1016/j.jconrel.2026.115145 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2026. Verfasst von Qinglin Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integr…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Radiopharmaceuticals, Lutetium, Radioisotopes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Abstract (Originalsprache)
Targeting programmed death ligand 1 (PD-L1) with proteolysis-targeting chimera (PROTAC) remains challenging due to the inability of visualized synergistic methods. Here, we report an integrated PD-L1-Targeted Radioligand with Protein Degradation (PRPD) platform that synergistically merges positron emission tomography (PET) imaging, targeted protein degradation, radiostimulation and radioligand therapy into a single small-molecule construct. We developed this radiotheranostic platform by designing amino acid-based linkers to conjugate PD-L1-targeting moiety, E3 ubiquitin ligase ligand, and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelator. PET imaging enabled visualization of PD-L1 biodistribution, transforming degrader dosing from an empirical "black box" into an image-guided intervention. [68Ga]Ga/[177Lu]Lu-DOTA-BLP showed specific, time-dependent tumor uptake in MC38-bearing mice, which was blocked by BMS1166. Mechanistically, the radioligand induced DNA damage and upregulated PD-L1 expression, thereby "priming" the tumor for enhanced targeted degradation. Combining a single 7.4 MBq dose of [177Lu]Lu-DOTA-BLP with DOTA-BLP significantly enhanced tumor suppression and survival versus monotherapy, with minimal toxicity. Collectively, this work established a PRPD strategy that provides a visual, synergistic, and precision-guided approach for dynamic protein degradation in immuno-oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, Fujian Engineering Research Center of Molec…
- Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou 363000, China.
- Department of Nuclear Medicine, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361003, China.
- Theranostics and Translational Research Center, National Infrastructures for Translational Medicine, Institute of Clinical Medicine & Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academ…
Förderung
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Zhang, Q., Liu, Q., Liu, J., Zhang, T., Wang, H., Shu, L., Wang, Y., Yang, T., Zhuang, R., Hong, L., Li, Y., Zhang, X., & Guo, Z. (2026). Integrating PD-L1-targeted radioligand with protein degradation for precision tumor theranostics. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2026.115145
Vancouver
Zhang Q, Liu Q, Liu J, Zhang T, Wang H, Shu L, et al. Integrating PD-L1-targeted radioligand with protein degradation for precision tumor theranostics. Journal of Controlled Release. 2026. doi:10.1016/j.jconrel.2026.115145
BibTeX
@article{Zhang2026,
author = {Zhang, Qinglin and Liu, Qi and Liu, Jia and Zhang, Tao and Wang, Hong and Shu, Linlin and Wang, Yanjie and Yang, Tao and Zhuang, Rongqiang and Hong, Liwei and Li, Yesen and Zhang, Xianzhong and Guo, Zhide},
title = {Integrating PD-L1-targeted radioligand with protein degradation for precision tumor theranostics},
journal = {Journal of Controlled Release},
year = {2026},
doi = {10.1016/j.jconrel.2026.115145}
}
EUVIMED